Eukaryotic initiation factor 4E variants alter the morphology, proliferation, and colony-formation properties of MDA-MB-435 cancer cells.
Eukaryotic initiation factor 4E (eIF4E) binds to the 5' m(7)G cap of mRNAs and is a focal point of regulation of initiation of mRNA translation. High levels of expression of eIF4E in many epithelial cancers, including breast, head and neck, colon, and bladder, correlate with increased tissue invasion and metastasis. To further examine the role of eIF4E in the biology of cancer cells, variants of eIF4E with impaired 5' cap binding function were expressed in MDA-MB-435 carcinoma cells. Cell lines overexpressing variants of eIF4E had impaired growth properties and exhibited a different morphology compared to cells expressing similar amounts of exogenous wild-type eIF4E or control cells. Cells expressing variant eIF4E did not form foci in culture and produced smaller colonies in soft agar compared to cells expressing wild-type eIF4E. In addition, analysis of polyribosomes for vascular endothelial growth factor (VEGF) mRNA demonstrated a shift from translationally active to inactive fractions in variant eIF4E cells, while GAPDH mRNA did not. The long G-C rich 5' untranslated region of VEGF mRNA is a feature of other mRNAs encoding growth regulating proteins that are predicted to have their translation enhanced by increases in eIF4E; whereas mRNA with shorter and less structured 5' UTRs, like that of GAPDH, are predicted to be largely unaffected. These data suggest that targeting the 5' cap-binding domain of eIF4E may be a viable option to slow cancer cell growth and alter the malignant phenotype.
Goldson
Tovë M
TM
Program in Biochemistry, Cell and Developmental Biology, Emory University School of Medicine, Atlanta, Georgia, USA.
Vielhauer
George
G
Staub
Eveline
E
Miller
Steve
S
Shim
Hyunsuk
H
Hagedorn
Curt H
CH
D020121:5' Untranslated Regions; D017209:Apoptosis; D001943:Breast Neoplasms / Q000235:genetics / Q000378:metabolism*; D002453:Cell Cycle; D049109:Cell Proliferation; D019008:Drug Resistance, Neoplasm; D004791:Enzyme Inhibitors / Q000494:pharmacology; D039561:Eukaryotic Initiation Factor-4E / Q000235:genetics* / Q000378:metabolism; D014644:Genetic Variation; D006801:Humans; D015151:Immunoblotting; D010442:Peptide Chain Initiation, Translational; D011132:Polyribosomes; D014176:Protein Biosynthesis; D012315:RNA Caps / Q000378:metabolism*; D019311:Staurosporine / Q000494:pharmacology; D014158:Transcription, Genetic; D014407:Tumor Cells, Cultured / Q000378:metabolism / Q000473:pathology; D014410:Tumor Stem Cell Assay; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics / Q000378:metabolism
D020121:5' Untranslated Regions; D004791:Enzyme Inhibitors; D039561:Eukaryotic Initiation Factor-4E; D012315:RNA Caps; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D019311:Staurosporine